GNRHR and cancer: The cytotoxic GnRH agonist Zoptarelin Doxorubicin (ZEXS-106, AN-152) was more potent than doxorubicin in the inhibition of in vitro cell growth in many GnRH receptor-positive cancer cell lines (28, 29).